Justina Petrullo

Long-term results comparing ranibizumab biosimilar SB11 vs reference ranibizumab (Lucentis) on neovascular age-related macular degeneration (nAMD) support biosimilarity between the treatments.

On this episode, we’re going to be recapping some of the biggest stories in the business space regarding biosimilars, including adalimumab preparation, partnerships for commercialization, and more.

Here are the top 5 biosimilar articles for the week of June 26, 2023.

It was found that cancer treatment, pediatric population, and coverage restriction of reference products were revealed as some of the strongest factors associated with biosimilar coverage decisions by US commercial health plans relative to reference products.

Here are the top 5 biosimilar articles for the week of June 19, 2023.

Enhancing pharmacists’ knowledge of biosimilars can assist in promoting their use and defeat misconceptions and misinformation related to generic drugs and biosimilars.

Here are the top 5 biosimilar articles for the week of June 12, 2023.

Infliximab (IFX) biosimilar SB2 was shown to be safe and effective in IFX-naïve patients and those who switched from a prior IFX reference or biosimilar.

Here are the top 5 biosimilar articles for the week of June 5, 2023.

If biosimilars are introduced to Spain, they will most likely save money in the pharmacological budget, according to a budget impact analysis model.

On this episode of Not So Different, we recap some of the biggest stories in the immunology space regarding biosimilars, including a new European approval, ustekinumab biosimilar delays, and more.

Here are the top 5 biosimilar articles for the week of May 29, 2023.

Here are the top 5 biosimilar articles for the week of May 22, 2023.

Findings from a recent study emphasize the need for improvement and changes regarding follow-on biologics and biosimilars in the global biosimilar market.

Here are the top 5 biosimilar articles for the week of May 15, 2023.

Here are the top 5 biosimilar articles for the week of May 8, 2023.

Here are the top 5 biosimilar articles for the week of May 1, 2023.

Biosimilar ranibizumab showed similar efficacy and safety in a recent study of the eyes of Indian patients with neovascular age-related macular degeneration.

A recent systematic review looked at the impact of different prices for infliximab in inflammatory bowel disease and the willingness-to-pay threshold around the world.

Here are the top 5 biosimilar articles for the week of April 17, 2023.

A retrospective study in Scotland found that multiple successive changes from originator infliximab to biosimilars seem to be safe and effective in patients with inflammatory bowel disease (IBD), irrespective of the number of switches.

Here are the top 5 biosimilar articles for the week of April 10, 2023.

Upon coming into her position as the new chair of the Association for Accessible Medicines (AAM), Christine Baeder discussed what she believes the future holds for biosimilars, good and bad, and the questions that still surround the insulin price cap.

Here are the top 5 biosimilar articles for the week of April 3, 2023.

Upon coming into her position as the new chair of the Association for Accessible Medicines (AAM) as well as chief operating officer for US generics and biosimilars at Teva Pharmaceuticals USA, Christine Baeder discusses her primary goals in this position, and the challenges that accompany them.

Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).

Here are the top 5 biosimilar articles for the week of March 20, 2023.

Here are the top 5 biosimilar articles for the week of March 13, 2023.

Comparable safety and efficacy were found between biosimilar FYB201 compared with reference ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD).

Here are the top 5 biosimilar articles for the week of March 6, 2023.